These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 22713663)

  • 1. Cisplatin plus paclitaxel and maintenance of bevacizumab on tumour progression, dissemination, and survival of ovarian carcinoma xenograft models.
    Oliva P; Decio A; Castiglioni V; Bassi A; Pesenti E; Cesca M; Scanziani E; Belotti D; Giavazzi R
    Br J Cancer; 2012 Jul; 107(2):360-9. PubMed ID: 22713663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cediranib combined with chemotherapy reduces tumor dissemination and prolongs the survival of mice bearing patient-derived ovarian cancer xenografts with different responsiveness to cisplatin.
    Decio A; Cesca M; Bizzaro F; Porcu L; Bettolini R; Ubezio P; Taraboletti G; Belotti D; Giavazzi R
    Clin Exp Metastasis; 2015 Oct; 32(7):647-58. PubMed ID: 26185056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor progression and metastatic dissemination in ovarian cancer after dose-dense or conventional paclitaxel and cisplatin plus bevacizumab.
    Bizzaro F; Falcetta F; D'Agostini E; Decio A; Minoli L; Erba E; Alessandro Peccatori F; Scanziani E; Colombo N; Zucchetti M; Bani MR; Ubezio P; Giavazzi R
    Int J Cancer; 2018 Nov; 143(9):2187-2199. PubMed ID: 29752717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II/III epithelial ovarian cancer.
    Konner JA; Grabon DM; Gerst SR; Iasonos A; Thaler H; Pezzulli SD; Sabbatini PJ; Bell-McGuinn KM; Tew WP; Hensley ML; Spriggs DR; Aghajanian CA
    J Clin Oncol; 2011 Dec; 29(35):4662-8. PubMed ID: 22067389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential activation of NF-κB signaling is associated with platinum and taxane resistance in MyD88 deficient epithelial ovarian cancer cells.
    Gaikwad SM; Thakur B; Sakpal A; Singh RK; Ray P
    Int J Biochem Cell Biol; 2015 Apr; 61():90-102. PubMed ID: 25681684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bevacizumab combination therapy: a review of its use in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.
    Dhillon S
    BioDrugs; 2013 Aug; 27(4):375-92. PubMed ID: 23728884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intraperitoneal administration of cisplatin plus bevacizumab for the management of malignant ascites in ovarian epithelial cancer: results of a phase III clinical trial.
    Zhao H; Li X; Chen D; Cai J; Fu Y; Kang H; Gao J; Gao K; Du N
    Med Oncol; 2015 Feb; 32(2):292. PubMed ID: 25609006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SMIFH2-mediated mDia formin functional inhibition potentiates chemotherapeutic targeting of human ovarian cancer spheroids.
    Ziske MA; Pettee KM; Khaing M; Rubinic K; Eisenmann KM
    Biochem Biophys Res Commun; 2016 Mar; 472(1):33-9. PubMed ID: 26898799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically.
    Garofalo A; Naumova E; Manenti L; Ghilardi C; Ghisleni G; Caniatti M; Colombo T; Cherrington JM; Scanziani E; Nicoletti MI; Giavazzi R
    Clin Cancer Res; 2003 Aug; 9(9):3476-85. PubMed ID: 12960140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The thrombospondin-1 mimetic ABT-510 increases the uptake and effectiveness of cisplatin and paclitaxel in a mouse model of epithelial ovarian cancer.
    Campbell NE; Greenaway J; Henkin J; Moorehead RA; Petrik J
    Neoplasia; 2010 Mar; 12(3):275-83. PubMed ID: 20234821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase 3 trial of bevacizumab in ovarian cancer.
    Perren TJ; Swart AM; Pfisterer J; Ledermann JA; Pujade-Lauraine E; Kristensen G; Carey MS; Beale P; Cervantes A; Kurzeder C; du Bois A; Sehouli J; Kimmig R; Stähle A; Collinson F; Essapen S; Gourley C; Lortholary A; Selle F; Mirza MR; Leminen A; Plante M; Stark D; Qian W; Parmar MK; Oza AM;
    N Engl J Med; 2011 Dec; 365(26):2484-96. PubMed ID: 22204725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer.
    O'Malley DM; Richardson DL; Rheaume PS; Salani R; Eisenhauer EL; McCann GA; Fowler JM; Copeland LJ; Cohn DE; Backes FJ
    Gynecol Oncol; 2011 May; 121(2):269-72. PubMed ID: 21315428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-line and maintenance therapy for ovarian cancer: current status and future directions.
    González-Martín A; Sánchez-Lorenzo L; Bratos R; Márquez R; Chiva L
    Drugs; 2014 Jun; 74(8):879-89. PubMed ID: 24848752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incorporation of bevacizumab in the primary treatment of ovarian cancer.
    Burger RA; Brady MF; Bookman MA; Fleming GF; Monk BJ; Huang H; Mannel RS; Homesley HD; Fowler J; Greer BE; Boente M; Birrer MJ; Liang SX;
    N Engl J Med; 2011 Dec; 365(26):2473-83. PubMed ID: 22204724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model.
    Mabuchi S; Terai Y; Morishige K; Tanabe-Kimura A; Sasaki H; Kanemura M; Tsunetoh S; Tanaka Y; Sakata M; Burger RA; Kimura T; Ohmichi M
    Clin Cancer Res; 2008 Dec; 14(23):7781-9. PubMed ID: 19047105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of fatty acid synthase in Middle Eastern epithelial ovarian carcinoma activates AKT and Its inhibition potentiates cisplatin-induced apoptosis.
    Uddin S; Jehan Z; Ahmed M; Alyan A; Al-Dayel F; Hussain A; Bavi P; Al-Kuraya KS
    Mol Med; 2011; 17(7-8):635-45. PubMed ID: 21442130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer.
    Furlong F; Fitzpatrick P; O'Toole S; Phelan S; McGrogan B; Maguire A; O'Grady A; Gallagher M; Prencipe M; McGoldrick A; McGettigan P; Brennan D; Sheils O; Martin C; W Kay E; O'Leary J; McCann A
    J Pathol; 2012 Apr; 226(5):746-55. PubMed ID: 22069160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II clinical trial of bevacizumab with albumin-bound paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma.
    Tillmanns TD; Lowe MP; Walker MS; Stepanski EJ; Schwartzberg LS
    Gynecol Oncol; 2013 Feb; 128(2):221-8. PubMed ID: 22960352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiangiogenic agents as a maintenance strategy for advanced epithelial ovarian cancer.
    Monk BJ; Dalton H; Farley JH; Chase DM; Benjamin I
    Crit Rev Oncol Hematol; 2013 May; 86(2):161-75. PubMed ID: 23137764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.